StockData
Kura Oncology, Inc. logo

Kura Oncology, Inc. (KURA) stock

KURANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$7.34−0.15 (-2.00%)

Close on Nov 18, 2026Market cap $652.97MP/E –Yield –

Kura Oncology operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Kura Oncology's operating cash flow for the twelve months ending Sep 30, 2026 was -$85.57M, down 197.5% year over year. For fiscal 2025 it was -$64.06M, down 147.7% from the year before. The highest annual figure on record is $134.32M in fiscal 2024.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$64.06M-147.7%
FY2024Dec 31, 2024$134.32M–
FY2023Dec 31, 2023-$124.82M–
FY2022Dec 31, 2022-$110.06M–
FY2021Dec 31, 2021-$104.55M–
FY2020Dec 31, 2020-$69.83M–
FY2019Dec 31, 2019-$54.76M–
FY2018Dec 31, 2018-$48.66M–
FY2017Dec 31, 2017-$28.44M–
FY2016Dec 31, 2016-$25.35M–
FY2015Dec 31, 2015-$17.93M–
FY2014Dec 31, 2014-$15.96K–
FY2013Dec 31, 2013-$23.23K–
FY2012Dec 31, 2012-$24.42K–
FY2011Dec 31, 2011-$22.68K–
FY2010Dec 31, 2010-$19.24K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$54.44M–
Q2 FY2026Jun 30, 2026-$62.55M–
Q1 FY2026Mar 31, 2026-$85.85M–
Q4 FY2025Dec 31, 2025$117.27M-56.4%
Q3 FY2025Sep 30, 2025-$80.63M–
Q2 FY2025Jun 30, 2025-$28.78M–
Q1 FY2025Mar 31, 2025-$71.93M–
Q4 FY2024Dec 31, 2024$269.13M–
Q3 FY2024Sep 30, 2024-$43.44M–
Q2 FY2024Jun 30, 2024-$42.53M–
Q1 FY2024Mar 31, 2024-$48.84M–
Q4 FY2023Dec 31, 2023-$34.31M–
Q3 FY2023Sep 30, 2023-$29.03M–
Q2 FY2023Jun 30, 2023-$25.62M–
Q1 FY2023Mar 31, 2023-$35.87M–
Q4 FY2022Dec 31, 2022-$26.53M–
Q3 FY2022Sep 30, 2022-$21.01M–
Q2 FY2022Jun 30, 2022-$30.34M–
Q1 FY2022Mar 31, 2022-$32.18M–
Q4 FY2021Dec 31, 2021-$23.37M–
Q3 FY2021Sep 30, 2021-$24.59M–
Q2 FY2021Jun 30, 2021-$28.07M–
Q1 FY2021Mar 31, 2021-$28.52M–
Q4 FY2020Dec 31, 2020-$18.31M–
Q3 FY2020Sep 30, 2020-$16.97M–
Q2 FY2020Jun 30, 2020-$14.73M–
Q1 FY2020Mar 31, 2020-$19.82M–
Q4 FY2019Dec 31, 2019-$13.93M–
Q3 FY2019Sep 30, 2019-$12.15M–
Q2 FY2019Jun 30, 2019-$14.43M–
Q1 FY2019Mar 31, 2019-$14.25M–
Q4 FY2018Dec 31, 2018-$10.21M–
Q3 FY2018Sep 30, 2018-$13.00M–
Q2 FY2018Jun 30, 2018-$12.59M–
Q1 FY2018Mar 31, 2018-$12.85M–
Q4 FY2017Dec 31, 2017-$7.47M–
Q3 FY2017Sep 30, 2017-$6.24M–
Q2 FY2017Jun 30, 2017-$6.11M–
Q1 FY2017Mar 31, 2017-$8.62M–
Q4 FY2016Dec 31, 2016-$6.74M–

More Kura Oncology figures

See a number that looks wrong?